Genetic polymorphism of cytochrome P450s results in clinically significant modifications in
patients' drug metabolizing capacities. CYP2D6 has a crucial role in the elimination of …

The cytochrome P450 2D6 (CYP 2D6) gene locus is challenging to accurately genotype due
to numerous single nucleotide variants and complex structural variation. Our goal was to …

The cytochrome P450 2D6 (CYP2D6) enzyme contributes to the metabolism and/or
bioactivation of approximately 25% of clinically used drugs. The CYP2D6 gene locus is …

CYP2D6 is a member of cytochrome P450 enzymes that metabolise over 25% of commonly
used drugs. Genetic polymorphisms can cause insufficient drug efficacy at usually …

Objective This study aims to determine the structure and frequency of haplotypes containing
either rs5758550 or rs16947, or both, together with other relevant CYP2D6 alleles …

CYP2D6 genetic polymorphisms are considered a major contributor to the large
interindividual variability in CYP2D6‐mediated drug metabolism, but fail to explain a …

Abstract CYP2D6 metabolizes nearly 25% of clinically used drugs. Genetic polymorphisms
cause large inter-individual variability in CYP2D6 enzyme activity and are currently used as …

Background/Aim: Accurate genotyping of CYP2D6 is challenging due to its inherent genetic
variation, copy number variation (duplications and deletions) and hybrid formation with …

Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the
growing number of alleles and their range of activity. This complexity poses a challenge in …

The emerging application of pharmacogenomics in the clinical trial setting requires careful
comparison with more traditional phenotyping methodologies, particularly in the drug …